Effects of silver nanoparticles in combination with antibiotics on the resistant bacteria Acinetobacter baumannii

International Journal of Nanomedicine

Volumn 11, Issue , 2016, Pages 3789-3800

  Wan, Guoqing ^a,b   Ruan, Lingao ^b,c   Yin, Yu ^b,c   Yang, Tian ^b,c   Ge, Mei ^b   Cheng, Xiaodong ^a,d  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b Shanghai Laiyi Center for Biopharmaceuticals RandD   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Acinetobacter baumannii; AgNPs; Antibiotic combination; Antisense RNA; Synergistic

Indexed keywords

CARBAPENEM; COMPLEMENTARY RNA; POLYMYXIN B; RIFAMPICIN; SILVER NANOPARTICLE; SILVER NITRATE; TIGECYCLINE; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; METAL NANOPARTICLE; SILVER;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; IN VIVO STUDY; MOUSE; MOUSE MODEL; NONHUMAN; PERITONITIS; ANIMAL; BETA-LACTAM RESISTANCE; C57BL MOUSE; CHEMISTRY; DRUG EFFECTS; HUMAN; ISOLATION AND PURIFICATION; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOGENICITY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; CARBAPENEMS; DRUG SYNERGISM; HUMANS; MALE; METAL NANOPARTICLES; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; PERITONITIS; RIFAMPIN; SILVER;

EID: 84983364564     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S104166     Document Type: Article

References (47)

1. Munoz-Price LS, Weinstein RA. Acinetobacter infection. New Engl J Med. 2008;358(12):1271-1281.
2. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21(3):538-582.
3. Tiwari V, Tiwari M. Quantitative proteomics to study carbapenem resistance in Acinetobacter baumannii. Front Microbiol. 2014;5: 512.
4. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infec. 2006;12(9):826-836.
5. Dizbay M, Tunccan OG, Sezer BE, Hizel K. Nosocomial imipenem-resistant Acinetobacter baumannii infections: epidemiology and risk factors. Scand J Infect Dis. 2010;42(10):741-746.
6. Brown JM, Dorman DC, Roy LP. Acute renal failure due to overdosage of colistin. Med J Australia. 1970;2(20):923-924.
7. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med. 1970;72(6):857-868.
8. Rodriguez Guardado A, Blanco A, Asensi V, et al. Multidrug-resistant Acinetobacter meningitis in neurosurgical patients with intraventricular catheters: assessment of different treatments. J Antimicrob Chemoth. 2008;61(4):908-913.
9. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol. 2007;5(12):939-951.
10. Caruso DM, Foster KN, Hermans MH, Rick C. Aquacel Ag in the management of partial-thickness burns: results of a clinical trial. J Burn Care Rehabil. 2004;25(1):89-97.
11. Chen S, Wu G, Zeng H. Preparation of high antimicrobial activity thiourea chitosan-Ag+ complex. Carbohyd Polym. 2005;60(1):33-38.
12. Cao XL, Cheng C, Ma YL, Zhao CS. Preparation of silver nanoparticles with antimicrobial activities and the researches of their biocompatibilities. J Mater Sci Mater Med. 2010;21(10):2861-2868.
13. Li WR, Xie XB, Shi QS, Zeng HY, Ou-Yang YS, Chen YB. Antibacterial activity and mechanism of silver nanoparticles on Escherichia coli. Appl Microbiol Biotechnol. 2010;85(4):1115-1122.
14. Mirzajani F, Ghassempour A, Aliahmadi A, Esmaeili MA. Antibacterial effect of silver nanoparticles on Staphylococcus aureus. Res Microbiol. 2011;162(5):542-549.
15. Kora AJ, Rastogi L. Enhancement of antibacterial activity of capped silver nanoparticles in combination with antibiotics, on model gram-negative and gram-positive bacteria. Bioinorg Chem Appl. 2013(8):319-355.
16. Huang L, Dai T, Xuan Y, Tegos GP, Hamblin MR. Synergistic combination of chitosan acetate with nanoparticle silver as a topical antimicrobial: efficacy against bacterial burn infections. Antimicrob Agents Chemother. 2011;55(7):3432-3438.
17. Jain J, Arora S, Rajwade JM, Omray P, Khandelwal S, Paknikar KM. Silver nanoparticles in therapeutics: development of an antimicrobial gel formulation for topical use. Mol Pharm. 2009;6(5):1388-1401.
18. Morones-Ramirez JR, Winkler JA, Spina CS, Collins JJ. Silver enhances antibiotic activity against gram-negative bacteria. Sci Transl Med. 2013;5(190):190ra181.
19. Sopirala MM, Mangino JE, Gebreyes WA, et al. Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2010;54(11):4678-4683.
20. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemoth. 2003;52(1):1-1.
21. Meng ZX, Nie J, Ling JJ, et al. Activation of liver X receptors inhibits pancreatic islet beta cell proliferation through cell cycle arrest. Diabetologia. 2009;52(1):125-135.
22. Goh S, Boberek JM, Nakashima N, Stach J, Good L. Concurrent growth rate and transcript analyses reveal essential gene stringency in Escherichia coli. PloS one. 2009;4(6):e6061.
23. Singh SB, Phillips JW, Wang J. Highly sensitive target-based whole-cell antibacterial discovery strategy by antisense RNA silencing. Curr Opin Drug Discov Devel. 2007;10(2):160-166.
24. Nakashima N, Goh S, Good L, Tamura T. Multiple-gene silencing using antisense RNAs in Escherichia coli. Methods Mol Biol. 2012;815:307-319.
25. Timurkaynak F, Can F, Azap OK, Demirbilek M, Arslan H, Karaman SO. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agents. 2006;27(3):224-228.
26. Yoon J, Urban C, Terzian C, Mariano N, Rahal JJ. In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2004;48(3):753-757.
27. Scheetz MH, Qi C, Warren JR, et al. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007;51(5):1621-1626.
28. Beer C, Foldbjerg R, Hayashi Y, et al. Toxicity of silver nanoparticles-nanoparticle or silver ion?. Toxicol Lett. 2012;208(3):286-292.
29. Foldbjerg R, Dang DA, Autrup H. Cytotoxicity and genotoxicity of silver nanoparticles in the human lung cancer cell line, A549. Arch Toxicol. 2011;85(7):743-750.
30. Fournier PE, Vallenet D, Barbe V, et al. Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genet. 2006;2(1):e7.
31. Rizzello L, Pompa PP. Nanosilver-based antibacterial drugs and devices: mechanisms, methodological drawbacks, and guidelines. Chem Soc Rev. 2014;43(5):1501-1518.
32. Flores CY, Minan AG, Grillo CA, Salvarezza RC, Vericat C, Schilardi PL. Citrate-capped silver nanoparticles showing good bactericidal effect against both planktonic and sessile bacteria and a low cytotoxicity to osteoblastic cells. ACS Appl Mater Interfaces. 2013;5(8):3149-3159.
33. Lambadi PR, Sharma TK, Kumar P, et al. Facile biofunctionalization of silver nanoparticles for enhanced antibacterial properties, endotoxin removal, and biofilm control. Int J Nanomed. 2015;10:2155-2171.
34. Smani Y, Docobo-Pérez F, Mcconnell MJ, et al. Acinetobacter baumannii-induced lung cell death: role of inflammation, oxidative stress and cytosolic calcium. Microb Pathogenesis. 2011;50(5):224-232.
35. Sarkar S, Leo BF, Carranza C, et al. Modulation of human macrophage responses to Mycobacterium tuberculosis by silver nanoparticles of different size and surface modification. PLoS One. 2015;10(11).
36. Perez F, Hujer AM, Hujer KM, et al. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Ch. 2007;51(10):3471-3484.
37. Gootz TD. The forgotten Gram-negative bacilli: what genetic determinants are telling us about the spread of antibiotic resistance. Biochem Pharmacol. 2006;71(7):1073-1084.
38. Lin L, Tan B, Pantapalangkoor P, et al. Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis. MBio. 2012;3(5):429-493.
39. Raetz CR, Whitfield C. Lipopolysaccharide endotoxins. Annu Rev Biochem. 2002;71:635-700.
40. Ray PH. Purification and characterization of 3-deoxy-D-manno-octulosonate 8-phosphate synthetase from Escherichia coli. J Bacteriol. 1980;141(2):635-644.
41. Meredith TC, Woodard RW. Characterization of Escherichia coli D-arabinose 5-phosphate isomerase encoded by kpsF: implications for group 2 capsule biosynthesis. Biochem J. 2006;395(2):427-432.
42. Donohue TJ. Targeted sigma factor turnover inserts negative control into a positive feedback loop. Mol Microbiol. 2009;73(5):747-750.
43. McClure WR, Cech CL. On the mechanism of rifampicin inhibition of RNA synthesis. J Biol Chem. 1978;253(24):8949-8956.
44. Habash MB, Park AJ, Vis EC, et al. Synergy of silver nanoparticles and aztreonam against Pseudomonas aeruginosa PAO1 biofilms. Antimicrob Agents Ch. 2014;58(10):5818-5830.
45. Jain J, Arora S, Rajwade JM, et al. Silver nanoparticles in therapeutics: development of an antimicrobial gel formulation for topical use. Mol Pharm. 2009;6(5):1388-1401.
46. Saballs M, Pujol M, Tubau F, et al. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. J Antimicrob Chemoth. 2006;58(3):697-700.
47. Mouton JW. Combination therapy as a tool to prevent emergence of bacterial resistance. Infection. 1999;27(Suppl 2):S24-S28.